NCT05116709 - Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

January 10, 2024

Study Completion Date

September 23, 2024

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

BAT6005 injection

Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.

Trial Locations (2)

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

Shanghai Oriental hospital, Shanghai